CLOZAPINE FOR PSYCHOSIS IN PARKINSONS-DISEASE

被引：94

作者：

PFEIFFER, RF

KANG, J

GRABER, B

HOFMAN, R

WILSON, J

机构：

[1] Section of Neurology, University of Nebraska Medical Center, Omaha, Nebraska

[2] Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska

来源：

MOVEMENT DISORDERS | 1990年 / 5卷 / 03期

关键词：

Clozapine; Parkinson's disease; Psychosis;

D O I：

10.1002/mds.870050310

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures. Copyright © 1990 Movement Disorder Society

引用

页码：239 / 242

页数：4

共 13 条

[1]

Girotti F, Soliveri P, Carella F, Et al., Dementia and cognitive impairment in Parkinson's disease, J Neurol Neurosurg Psychiatr, 51, pp. 1498-1502, (1988)

[2]

Andersen PH, Nielsen EB, Gronvald FC, Braestrup C, Some atypical neuroleptics inhibit [<sup>3</sup>H]SCH 23390 binding, Eur J Pharmacol, 120, pp. 143-144, (1986)

[3]

Andersen PH, Braestrup C, Evidence for different states of the dopamine D1 receptor: clozapine and fluperlapine may preferentially label an adenylate cyclase‐coupled state of the D1 receptor, J Neurochem, 47, pp. 1822-1831, (1986)

[4]

Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S, Clozapine: plasma levels and prolactin response, Psychopharmacology, 73, pp. 184-187, (1981)

[5]

Skarsfeldt T, Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurons in rats, Life Sci, 42, pp. 1037-1044, (1988)

[6]

(1985)

[7]

Tully EM, Clozapine: a review, Am J Prev Psychiatr Neurol, 1, pp. 19-23, (1988)

[8]

Fahn S, Elton RL, Unified Parkinson's disease rating scale, Recent developments in Parkinson's disease, 2, pp. 153-163, (1987)

[9]

Scholz E, Dichgans J, Treatment of drug‐induced exogenous psychosis in parkinsonism with clozapine and fluperlapine, Eur Arch Psychiatr Neurol Sci, 235, pp. 60-64, (1985)

[10]

Friedman JH, Max J, Swift R, Idiopathic Parkinson's disease in a chronic schizophrenic patient: long‐term treatment with clozapine and L‐dopa, Clin Neuropharmacol, 10, pp. 470-475, (1987)

← 1 2 →